# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-218195
Filing Date
2026-05-12
Accepted
2026-05-12 07:35:41
Documents
90
Period of Report
2026-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | sabs-20260331.htm iXBRL | 10-Q | 3018875
2 | EX-10.2 | sabs-ex10_2.htm | EX-10.2 | 19112
3 | EX-31.1 | sabs-ex31_1.htm | EX-31.1 | 27033
4 | EX-31.2 | sabs-ex31_2.htm | EX-31.2 | 27114
5 | EX-32.1 | sabs-ex32_1.htm | EX-32.1 | 11641
6 | EX-32.2 | sabs-ex32_2.htm | EX-32.2 | 11984
7 | GRAPHIC | img84486182_0.gif | GRAPHIC | 95030
| Complete submission text file | 0001193125-26-218195.txt |  | 14591787

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
8 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | sabs-20260331.xsd | EX-101.SCH | 1877181
94 | EXTRACTED XBRL INSTANCE DOCUMENT | sabs-20260331_htm.xml | XML | 3171984

Mailing Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140
Business Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140 305-845-2813
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

EIN.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39871 | Film No.: 26965892
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)